Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 07:00PM GMT
Release Date Price: $35.78 (+3.62%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Welcome, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at Barclays. It's my great pleasure to introduce our next presenting company, REGENXBIO. At the Zoom meeting with me, we have Ken Mills, Chief Executive Officer; Vit Vasista, Chief Financial Officer; and also Steve Pakola, Chief Medical Officer.

With that, I will hand over to you, Ken.

Kenneth T. Mills
REGENXBIO Inc. - CEO, President & Director

Thank you, Gena, and thanks to you and your team from Barclays for hosting us today. I'm going to start off with a quick corporate overview of REGENXBIO, and then circle back with Gena for some questions-and-answer session.

Starting my screen share. So my presentation this morning may include some forward-looking statements. The details behind the legal ramifications of this can be found in our SEC documents and filings.

REGENXBIO is a company that's seeking to improve lives through the curative potential of gene therapy. We have multiple ongoing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot